Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $59.08, for a total transaction of $415,923.20. Following the completion of the transaction, the chief executive officer directly owned 31,080 shares of the company’s stock, valued at approximately $1,836,206.40. The trade was a 18.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jack Bendheim also recently made the following trade(s):
- On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total transaction of $384,665.60.
- On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
- On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80.
- On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
- On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.
- On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
- On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total transaction of $361,644.80.
- On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80.
- On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00.
- On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.
Phibro Animal Health Price Performance
PAHC stock opened at $57.07 on Friday. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $60.08. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. The company has a 50-day moving average price of $53.37 and a 200 day moving average price of $45.11. The stock has a market cap of $2.31 billion, a PE ratio of 25.36, a P/E/G ratio of 0.83 and a beta of 0.69.
Phibro Animal Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio is 21.33%.
Analyst Ratings Changes
PAHC has been the topic of a number of recent analyst reports. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, Citigroup assumed coverage on shares of Phibro Animal Health in a research note on Wednesday. They issued a “neutral” rating and a $62.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and a consensus price target of $42.40.
Check Out Our Latest Research Report on PAHC
Hedge Funds Weigh In On Phibro Animal Health
Hedge funds and other institutional investors have recently modified their holdings of the business. 1620 Investment Advisors Inc. boosted its stake in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares in the last quarter. Hughes Financial Services LLC acquired a new stake in Phibro Animal Health in the third quarter valued at approximately $40,000. Rothschild Investment LLC boosted its stake in Phibro Animal Health by 2,500.0% in the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after acquiring an additional 1,000 shares in the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in Phibro Animal Health in the third quarter valued at approximately $61,000. 99.34% of the stock is currently owned by institutional investors.
More Phibro Animal Health News
Here are the key news stories impacting Phibro Animal Health this week:
- Positive Sentiment: Recent quarterly results and FY‑2026 guidance support the rally — Phibro beat EPS and revenue expectations and set FY‑2026 EPS guidance of roughly 2.93–3.10, helping justify the higher share price. MarketBeat PAHC coverage
- Positive Sentiment: Upgrades and positive analyst notes (e.g., Zacks upgrade to Strong Buy and reaffirmations from boutique shops) have increased investor interest and buying pressure. Analyst coverage summary
- Neutral Sentiment: Citigroup initiated coverage with a “neutral”/hold rating and a $62 price target (roughly single‑digit upside vs. current levels). That provides formal coverage but not a buy endorsement. Citigroup initiation
- Neutral Sentiment: Media discussion about whether it’s “too late” after a ~234.5% rally is drawing attention — this can attract momentum traders but also encourages re‑rating/valuation debate among longer‑term investors. Yahoo Finance article
- Negative Sentiment: CEO Jack Bendheim has sold multiple blocks of shares recently (most recently 7,040 shares at ~$54.64 on Apr 16). While the trades were executed under a pre‑arranged Rule 10b5‑1 plan (which limits informational inference), repeated insider sales can create short‑term caution among investors. InsiderTrades report
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
See Also
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
